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ABSTRACT 
The potential application for stem cell therapy is vast and its development for 
use in ischaemic stroke is still at its infancy. Access to stem cells for research 
is contentious but various sources are obtainable from both animals and 
humans. Despite a limited understanding of their mechanisms of action, clinical 
trials assessing stem cells in human stroke have been performed. Trials are 
also underway evaluating haematopoietic precursors mobilised with 
granulocyte-colony stimulating factor, an approach offering an autologous 
means of administrating stem cells for therapeutic purposes. This review 
summarises current knowledge in regard of stem cells and their potential for 
helping improve recovery after stroke. 
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INTRODUCTION 
Stroke is the third leading cause of death worldwide and is devastating to both 
patients and carers. More than half of all stroke survivors are left dependent 
on others for everyday activities (1). Each year there are 110,000 first strokes 
and 30,000 recurrent strokes in the United Kingdom; 10,000 strokes occur in 
people younger than 65 and 60,000 people die of stroke. More than five per 
cent of NHS and social service resources are consumed by stroke patients (2). 
Finding an effective acute intervention for this burden, which is present 
worldwide, is proving challenging: aspirin has a wide utility but modest 
efficacy, and alteplase the converse; anticoagulation has proven ineffective (3) 
and various approaches with neuroprotection remain under investigation (4). 
In fact, with the exception of aspirin, thrombolytic therapy and 
hemicraniectomy, clinical management is primarily based on supportive care in 
a stroke unit (5-7). 
 
One potentially important area of development in the treatment of stroke is 
the use of stem cells to enhance recovery. The definition of a stem cell 
continues to evolve as more knowledge is gained on the subject. It currently 
requires demonstration of two properties: the capacity for self-renewal and the 
ability to differentiate into multiple cell types (potency) (8). A progenitor cell 
also has these characteristics but has a more restricted potential, i.e. it can 
only differentiate into a limited number of cell types and has a reduced 
capacity for self-renewal (8). Stem cell transplant trials are already underway 
in conditions such as diabetes, cancer, neurodegenerative disease (e.g. 
Parkinson’s Disease), and heart disease (9-12). This review describes the 
current situation with the use of stem cells in ischaemic stroke, with particular 
reference to haematopoietic stem cells. 
 
SOURCES OF STEM CELLS FOR STROKE THERAPY 
Although a commonly held belief that ‘the brain does not regenerate’, it is now 
accepted that spontaneous post-natal (adult) neurogenesis can occur (13). A 
number of cell sources for stem cell transplantation are available and these can 
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be categorised in several dimensions: exogenous or endogenous sources of 
cells; embryonic, foetal or adult derivation; neural or non-neural origin; and 
pluripotential (which can divide indefinitely) or multipotential (which usually 
regenerate their ‘own tissue’ but have the ability to transdifferentiate into 
other tissue cell types). 
 
Neural progenitor cells (NPCs) 
In both human and animal adult brain there are multiple sites of ongoing 
neuronal and glial formation. Human neural stem cells reside in the 
periventricular regions and cerebral cortex during development and have been 
shown to persist into adulthood in a number of sites including the dentate 
gyrus of the hippocampus, substantia nigra and olfactory bulb (13-17). Animal 
models demonstrate that ischaemic stroke is associated with differentiation of 
cells into neurons phenotypically similar to those lost in the ischaemic lesion 
(18), a finding suggesting that the adult brain has capacity for self repair. As 
observed in rodents, subventicular and hippocampal cells from adult human 
brain can be expanded in vitro, differentiate into all three neural cell lineages 
(neuronal, astrocytic and oligodendroglial) (19) and can improve functional 
recovery when administered intravenously into a rat model of stroke (20). 
Conflicting results have been seen with human foetal derived neural stem cells 
transplanted into stroke rats (21); though the cells were shown to migrate 
throughout the damaged striatum, cells within the transplant core were 
undifferentiated and of immature neural lineage. Virtually none of the grafted 
cells differentiated into astrocytes or oligodendrocytes. However, to date, there 
is no set of markers that precisely identifies a neural stem cell and 
distinguishes it from other more limited progenitors, precursors or 
differentiated cells. The isolation of true neural stem cells and the regions in 
which they exist remain under investigation. For example, cells cultured from 
areas outside of the striatal subventricular zone in the post-natal brain 
demonstrate a more limited capacity for self renewal than well characterised 
ventricular subependymal neural stem cells (22). The formal identification of 
cells as neural stem cells still requires functional demonstration of 
multipotency, self-renewal and longevity.  
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Embryonic and foetal stem cells  
Sufferers of Parkinson’s Disease appear to have benefited from human foetal 
stem cell transplantation (11), but these cells are in limited supply and their 
use is fraught with ethical issues in obtaining human tissue for the purpose of 
obtaining stem cells. Embryonic stem cells are capable of producing large 
quantities of neural progenitors and, in principle, are pluripotent with unlimited 
expandability; murine embryonic stem cells have been observed to 
differentiate into neurons and glial cells when grafted into stroke rats (23, 24) 
and survive for up to 12 weeks. A potential drawback is that they tend to 
develop a heterogeneous mix of neural precursors and differentiated neurons 
or glia as well as residual stem cells and a small percentage of non-neural cells 
(25); the challenge here is to direct differentiation into producing a 
homogenous cell population. Another disadvantage is their potential for 
malignant transformation. For example, when undifferentiated murine 
embryonic stem cells were xenotransplanted into a rat model of stroke, 
neuronal differentiation was observed; when the same cells were transplanted 
into the homologous mouse brain, the cells did not migrate and they produced 
a highly malignant teratocarcinoma (26). 
 
Porcine foetal cells 
Patients with Parkinson’s Disease and Huntington’s Disease have undergone 
stem cell transplantation with foetal porcine neurons (27, 28) and this donor 
source is considered as relatively safe. However, the insertion of foreign cells 
brings the risk of rejection and the need for chronic immunosuppression. 
Furthermore, xenotransplantation may lead to transmission of porcine viruses, 
such as the porcine endogenous retrovirus, although one study did not find 
any evidence of this problem (29). 
 
Immortalised cell lines 
Cells derived by either genetic transformation or cultured embryonic and adult 
tissue offer a ready and unlimited source of cells, thereby reducing ethical 
concerns in obtaining aborted foetal tissue. For example, LBS-Neurons (Layton 
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Bioscience, Inc) were produced from a NT2/D1 human precursor cell line and 
induced to differentiate into neurons by the addition of retinoic acid. This cell 
line was originally derived from a human testicular tumour more than 20 years 
ago (30) and the final product gives a neuronal cell population virtually 
indistinguishable from terminally differentiated post-mitotic neurons (31). 
Malignant transformation following therapeutic transplantation of this cell type 
is a key concern for this approach. 
 
Stem cells derived from the blood and bone marrow 
Bone marrow stromal cells, umbilical cord blood and peripheral blood stem 
cells (PBSCs) are alternative sources of stem cell and their use carries minimal 
ethical unease when transplanted in an autologous manner. Bone marrow and 
umbilical cord blood are composed of multiple cell types containing 
haematopoietic and endothelial precursors (CD34+ cells) and non-
haematopoietic cells (mesenchymal stromal or CD34- cells). Approximately 10-
20% of bone marrow derived stem cells (BMSCs) are multipotent, with the 
remaining representing more differentiated committed cells (32). It is 
contentious whether these latter cells can transdifferentiate into neural cells; 
bone marrow derived cells can adopt neural characteristics (33-35) but the 
cells are atypical (spherical in nature with few processes (36)) and it is argued 
that transplanted cells spontaneously fuse with recipient cells and 
subsequently adopt their phenotype (37). Additionally, murine haematopoietic 
stem cells demonstrate an age-dependent dimunition of self-renewal, 
increased apoptosis and functional exhaustion under conditions of stress (38). 
Nevertheless, bone marrow derived stem cells improved outcome in 
experimental models of stroke (39, 40), and preserved cognitive function has 
also been seen with intravenous transplantation of mesenchymal stem cells 
into rat models of Middle Cerebral Artery occlusion (MCAo) (41). Similarly, 
behavioural and neurological improvement has been demonstrated with 
intravenous infusion of CD133+ cells in stroke rats (42); the stem cell marker 
CD133, a transmembrane cell surface antigen, is specifically expressed on 30-
75% of CD34+ cells and has potential benefit for stem cell transplantation 
since they are less differentiated. However, in this particular study (42), 
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behavioural improvement was only apparent using intravenous transplantation 
within 1 hour of the stroke (compared to delivery at 3 days post stroke) and 
reduction of cerebral infarct size was only seen when the cells were 
transplanted intracerebrally. 
 
Haematopoietic stem cells (CD34+ cells) 
Haematopoietic stem cells (HSCs) are adult stem cells (the origins of which are 
poorly understood) that give rise to all blood cell types including myeloid and 
lymphoid lineages. The CD34 molecule is a cell surface glycoprotein expressed 
on HSCs and used to facilitate their identification, though CD34-ve HSCs may 
exist (43). An ischaemic stroke leads to mobilisation of CD34+ cells (as also 
seen in myocardial infarction (44)), which occurs in bursts over the first 10 
days post stroke (45, 46); those with higher levels of CD34+ cell mobilisation 
have a better neurological outcome (45). The origin and fate of these cells are 
not known. Interestingly, circulating CD34+ counts are inversely related to 
subsequent recurrent cerebral infarction (47) and cardiovascular events (48). 
Considering these changes, it is reasonable to hypothesis that promoting the 
mobilisation of CD34+ cells may be of therapeutic benefit. In one recent study, 
mononuclear cells were isolated and cultured ex vivo from the peripheral blood 
of 30 acute stroke patients (49). These ‘outgrowth’ cells demonstrated a 
heterogenous population of cells with endothelial and neuronal morphologies; 
the neuronal outgrowth cells, transplanted 4 days post ischaemia into rat 
brains, survived (for over 6 months), differentiated into neuronal phenotypes 
and helped improve functional recovery. 
 
Mobilisation of stem cells 
Production of stem cells derived from the bone marrow are stimulated by 
hormones called colony stimulating factors (CSFs). Stem cell factor (SCF) 
regulates differentiation of CD34+ stem cells; granulocyte-colony stimulating 
factor (G-CSF) – neutrophils; erythropoietin (EPO) – red blood cells; 
granulocyte-macrophage-colony stimulating factor (GM-CSF) – macrophages 
and neutrophils; macrophage-colony stimulating factor (M-CSF or CSF-1) – 
monocytes; and thrombopoietin (TPO) – platelets. SCF, G-CSF, EPO, GM-CSF 
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and M-CSF have all been evaluated in pre-clinical models of ischaemic stroke 
(50-54); studies using G-CSF and EPO have advanced to human stroke trials. 
 
Granulocyte-colony stimulating factor (G-CSF) 
Intentional recruitment of haematopoietic CD34+ stem cells from bone marrow 
to peripheral blood with G-CSF is a clinical process termed peripheral blood 
stem cell (PBSC) mobilisation. Although the mechanism involved in this 
process is largely unknown, G-CSF alone or with chemotherapy is used 
routinely in clinical practice to reduce the duration of neutropenia in patients 
with haematological disease, or for mobilising and harvesting PBSCs for 
subsequent autologous or allogenic infusion. Its use in stroke is novel and 
under investigation in both animals and humans. For therapeutic purposes, 
autologous marrow stem cells could be obtained but this is unattractive in view 
of the need for multiple marrow punctures.  
 
In rat and mice models of ischaemic stroke, a number of groups have 
demonstrated G-CSF to be neuroprotective at various doses (55), in the 
presence of thrombolysis (56, 57), induce functional recovery (52, 58) and 
promote angiogenesis (58-60) and neurogenesis (58, 60, 61). All have 
illustrated that G-CSF causes a reduction in stroke lesion volume. However, G-
CSF can also lead to impaired behavioural function (62) and may have no 
benefit when given in the chronic phase of stroke (63) or in global ischaemic 
models (64). 
 
The mechanisms of action of G-CSF are probably multimodal. Angiogenesis 
and neurogenesis may occur secondary to CD34+ cell mobilisation but further 
work on the effects of G-CSF reveal that neurons and adult neural stem cells 
express a G-CSF receptor and its expression is induced by ischaemia (61). Pre-
clinical studies also show that G-CSF may have an anti-inflammatory role as it 
causes suppression of iNOS (65) and other inflammatory mediators such as 
interleukin-1 beta (66). It is thought that the neuroprotective effect of G-CSF 
is mediated by anti-apoptotic activity via up-regulation of Stat 3 (signal 
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transducer and activator of transcription 3) and the JAK/STAT signaling 
pathway (65).  
 
MECHANISMS OF RECOVERY AFTER STROKE 
Motor, sensory and cognitive dysfunction are common results of stroke and 
cause considerable disability and social distress. Restoration of movement and 
motor function forms the focus of rehabilitation based on physical therapy. 
Recovery of motor and cognitive function occurs to a variable degree through a 
number of pathways (67-71): unmasking – recruitment of existing but latent 
connections; sprouting – development of new neural connections (including 
synaptogenesis); long term potentiation – enhancement of memory and 
learning; resolution of diaschisis (remote functional depression); and 
neurogenesis – replacing lost neurones. Additionally, animal models of 
recovery of function after stroke reveal that repetitive practice or exercise can 
evoke endogenous neurogenesis and the expression of signalling molecules 
(perhaps better called ‘regenokines’) such as brain derived neurotrophic factor 
(BDNF), which then promotes neuronal repair, enhancing learning and memory 
(72). 
 
There is increasing interest in the use of interventions that might augment 
these normal restorative events after stroke, either pharmacologically with 
drugs such as amphetamine (‘rehabilitation pharmacology’) (73) or, more 
recently, through the use of stem cells. Advances in molecular biology are 
creating opportunities to use cellular therapies to enhance neuronal 
regeneration in adjunct to a neuro-rehabilitation programme. However, the 
mechanism by which stem cells may improve recovery is still poorly 
understood. There are two theories: neuroprotection - preventing damaged 
neurons undergoing cell death in the acute phase of cerebral ischaemia; and 
neurorepair - the repair of broken neuronal networks in the chronic phase of 
cerebral ischaemia. When considering how stem cells promote recovery, there 
is probably some overlap between these two groups.  
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Reduced apoptosis and inflammation 
An intervention that reduces stroke lesion size, usually by decreasing cell 
death within the ischaemic penumbra, indicates neuroprotective activity. This 
mechanism has been demonstrated with intravenous administration of 
haematopoietic stem cells and via intracerebral grafting of human neural stem 
cells in ischaemic stroke models (74, 75). However, a reduction in lesion 
volume is not always seen with transplantation of stem cells from a variety of 
sources (39, 76-78), this perhaps relating to the method and time of 
administration post stroke. 
 
Neuroprotection could also be secondary to reducing inflammatory responses. 
It is likely that stem cells play a pivotal role in the regulation of the 
inflammatory cascade via the production of cytokines and growth factors and it 
might be expected that a cell transplant would induce or exacerbate 
inflammation. An exaggerated inflammatory response in the peri-infarct area 
has been observed in a murine model of stroke treated with G-CSF (62). 
Conversely, the use of human cord blood cells in a rat model of stroke had the 
opposite effect by decreasing the inflammatory infiltrate as indicated by a 
reduction in the expression of pro-inflammatory cytokines (79).  
 
Recruitment of endogenous neural progenitor cells (NPC) 
Since progenitor cells exist within the brain, and neurones, glia and vascular 
cells can be renewed, it might be thought that significant neurogenesis might 
take place after stroke. Although there are a number of rodent models 
investigating endogenous neurogenesis in cerebrovascular disease (80-82), 
few studies have been reported in humans. In one, histological examination 
was performed in an 84 year old patient who suffered a stroke 1 week prior to 
death (83). Using a neural stem cell label, large numbers of neural stem cells, 
vascular endothelial growth factor-immunopositive cells, and new blood vessels 
around the region of infarction were present suggesting the presence of 
ischaemia induced NPC recruitment and neovascularisation. Other studies have 
also shown the presence of ischaemia-induced endogenous neurogenesis (18). 
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Growth factors such as BDNF and nerve growth factor (NGF) are involved in 
the regulation of brain stem cell division and differentiation. Enhancing these 
naturally occurring neurogenic factors through exogenous administration offers 
a potential treatment for stroke. However, only one molecule has been tested 
to date; in a phase II/III trial (286 patients) of basic fibroblast growth factor 
(bFGF), treatment was ineffective, even showing a trend to hazard, and caused 
leucocytosis and hypotension (84). The use of treatments targeting a single 
growth factor pathway in pathophysiological states might have limited effect, 
as has been seen with numerous neuroprotectants with unimodal mechanisms 
of action (85). Stem cells offer a potential multimodal mechanism of action, 




Whether stem cells can improve recovery by replication and differentiation 
(‘direct neurogenesis’), and thereby replace damaged brain cells and 
reconstruct neural circuitry, remains unclear with limited and conflicting 
evidence. In rats with induced MCAo, transplanted neurospheres survived 4 
weeks post transplant with the majority of migrating cells expressing a 
neuronal phenotype (including doublecortin, -tubulin and glial fibrillary acid 
protein [GFAP] markers) (76). Neurospheres derived from adult stroke rats can 
also differentiate into glia (as well as neurons), and can migrate towards the 
ischaemic lesion (86). A human neural stem cell line (CTX0E03, ReNeuron 
Group plc (87)), derived from human somatic stem cells following genetic 
modification with an immortalising gene, can differentiate into neurons and 
astrocytes, and induce significant improvements in both sensorimotor and 
gross motor function in the rat MCAO model of stroke 6 to 12 weeks post 
grafting (88). Finally, in mice incapable of developing cells of the myeloid and 
lymphoid lineages, transplanted adult bone marrow cells (BMCs) migrated into 
the brain and differentiated into cells that expressed neuron specific antigens 
(NeuN, a nuclear protein that is found exclusively in neurons) (34). In 
contrast, no evidence of neural-like cells was found in another study of mice 
transplanted with BMCs (89). Other groups have also failed to detect 
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differentiation of haematopoietic stem cells into neural tissue (90). In fact, in 
the positive studies showing cell differentiation into a neural phenotype, only 
small numbers of cells survived suggesting that integration into host circuitry 
is not the only or main mechanism of action to enhance functional recovery. 
Nevertheless, the finding that response may depend on the number of cells 
administered (‘dose response’) is compatible with beneficial effects being 
mediated by cell replacement (91).  
 
Angiogenesis 
Neurogenesis alone will not lead to recovery since neurones need nutritional 
support from the vasculature and new vessels will need to develop. 
Angiogenesis has been found experimentally, as shown when bone marrow-
derived CD34+ cells were administered intravenously to mice 48 hours after 
stroke induction (74); accelerated neovascularisation occurred in comparison 
with mice injected with CD34- cells. Furthermore, administration of an 
antiangiogenic agent prevented the beneficial effect of CD34+ precursors (74). 
While angiogenesis could reflect differentiation of haematopoietic stem cells 
into blood vessel wall cells, an indirect effect is also likely since human CD34+ 
cells have been shown to secrete numerous angiogenic factors, including 
vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF-
1) (92). Hence, a rich vascular environment mediated by CD34+ cells might 
enhance subsequent neuronal regeneration.  
 
Plasticity 
Neuroplasticity refers to organisational changes in the brain so that individual 
neurones or networks adapt their function. This theory forms the basis for 
goal-directed, therapeutic rehabilitation. Stem cells may augment this process 
via various mechanisms of recovery, including sprouting and unmasking, but 
the evidence in stroke remains limited. Sprouting has been seen in 
experimental stroke following intravenous administration of human bone 
marrow stromal cells to rats; a 50% reduction in lesion volume was seen in 
comparison to saline-treated controls (93). In contrast to this, treatment with 
CONFIDENTIAL Re-submission 12/5/8 
Page 12 of 26 
human umbilical cord blood cells did not improve sensorimotor or cognitive 
outcome in stroke rats (78) in one of the few reported negative studies. 
 
Stem cell migration 
Several experimental paradigms have tested the fate of stem cells when not 
implanted directly into the site of injury. Under ischaemic conditions, 
transplanted bone marrow stromal cells selectively migrated to the ischaemic 
hemisphere of the damaged brain in rats (94) suggesting that the injured brain 
might specifically attract these cells. In one study, cultured embryonic cells 
(D3 cell line) were incubated with superparamagnetic iron-oxide nanoparticles 
(to confer visibility with magnetic resonance imaging [MRI]) and then grafted 
into the normal hemisphere of rats given transient MCA ischaemia 14 days 
earlier; contrast was tracked with T2* weighted MRI, which is highly sensitive 
to iron-label, and was seen to migrate to the ischaemic hemisphere by 3-7 
days and remain there for at least 20 days post implantation (95). In another 
study, G-CSF was given to normal human donors to mobilise peripheral blood 
stem cells, the CD34+ cells being extracted, separated immunomagnetically 
and labelled (96). The cells were then grafted into the normal hemisphere of 
rats given permanent MCAO ischaemia 7 days earlier. Cells were tracked by 
T2* MRI migrating to the lesion side with label remaining for at least 21-50 
days (96). Furthermore, human cells were present in the lesion, corpus 
callosum and subventricular zone when assessed by immunohistochemistry. 
Uncertainty remains with the processes behind stem cell migration though 
some inroads have been made. For example, it appears that stromal cell 
derived factor–1alpha (SDF-1alpha) and its receptor CXCR4 play an important 
role in the migration of intravenously transplanted MSCs (97). 
 
CLINICAL TRIALS OF STEM CELL TRANSPLANTATION AFTER STROKE 
There have been no large-scale clinical trials of stem cell transplantation in 
stroke. However, a number of safety studies have been reported (see table 1). 
 
In one non-controlled study, cultured neuronal cells, derived from an 
immortalised cell-line (LBS-Neurons), were transplanted into 12 patients (age 
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44-75) with stroke (primarily involving basal ganglia) (98). Patients received 
one of 2 doses of cells via CT-guided, stereotactic-targeting of cell implants; 
immunosuppression was covered with intravenous methylprednisolone (during 
surgery) and then cyclosporine for 8 weeks. Although functional outcome could 
not be assessed since the study was too small and had no control group, PET 
scanning in 6 patients showed increased metabolic activity, suggesting either 
cell viability or the presence of inflammatory cells (98). Interestingly, detailed 
histopathological study of the brain from one of the study patients who died at 
27 months after cell implantation identified survival of transplanted neuronal 
cells with no evidence of malignancy (99). The potential for de-differentiation 
of transplanted cells back to a malignant state is a theoretical concern with the 
use of transformed stem cells derived from tumours, although pre-clinical 
studies in mice with this cell line (NT2) have demonstrated no toxicity or 
tumourgenicity (100).  
 
As a follow up to this study, the same researchers performed a phase two 
randomised trial, using the same cell line, in 18 patients (101). Patients were 
between 18 and 75 years and had a fixed motor deficit that was stable for at 
least 2 months. The treated group (n=14) received one of two doses of 
implanted cell and a rehabilitation programme; the control group (n=4) had 
rehabilitation alone. The primary outcome measure, the change in the 
European Stroke Scale motor score at 6 months, did not differ between the 
two groups (101). 
 
A safety and feasibility study of the use of foetal porcine cells in patients 1.5-
10 years after a middle cerebral artery infarct (affecting the striatum) has also 
recently been performed (102). To prevent rejection, cells were pre-treated 
with anti-MHC1 antibody and no immunosuppressive drugs were given to the 
patients. Of the 12 planned patients, only 5 patients entered the study 
following which the US Federal Drug Administration halted the trial 
prematurely after 2 patients developed serious adverse events. One patient 
suffered a cortical vein occlusion secondary to the surgical procedure, and the 
other experienced generalised and partial seizures while hyperglycaemic. 
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These observations highlight the potential risks with intracranial 
transplantation of stem cells and suggest that other modes of delivery of stem 
cells should be considered.  
 
One such alternative is to use autologous stem cells. A recent randomised 
controlled trial tested mysenchymal stem cells (MSCs) in patients with middle 
cerebral artery territory infarction (103). 5 patients with persistent 
neurological deficit 7 days after their ischaemic stroke were allocated to 
receive intravenous MSCs and 25 patients acted as controls (no additional 
intervention and no sham procedure). MSCs were acquired from bone marrow 
aspirates and then cultured ex vivo to obtain sufficient quantities before re-
injection into the patient 4-6 and then 7-9 weeks after symptom onset. At 1 
year, 10 patients in the control group were lost to follow-up but no serious 
adverse events such as infection or tumour formation had occurred. The study 
has demonstrated feasibility in administering ex-vivo cultured MSCs but the 
authors have been heavily criticised for both its methods and conclusions 
reached (104) and have since issued an apology for having plagiarised sections 
of their discussion (105). 
G-CSF in clinical stroke 
Three small, randomised controlled trials have assessed the safety of 
recombinant G-CSF after ischaemic stroke (table 2). A recently completed 
phase IIa dose-escalation trial assessed G-CSF in 36 patients (G-CSF, n=24; 
placebo, n=12) with sub-acute ischaemic stroke (106). Patients were treated 
between 7-30 days post ictus with increasing doses of G-CSF (1-10g/kg given 
either once or daily for 5 days) given subcutaneously. G-CSF increased 
circulating CD34+ counts 10-fold (as measured by flow cytometry) in a dose-
dependent manner and with the peak level occurring at day 5. A dose-
dependent increase in white cell count at day 3 and decrease in platelet count 
also occurred, expected effects of G-CSF. Serious adverse event rates did not 
differ although the frequency of infection was non-significantly higher in G-CSF 
treated patients (29% vs. 25%); stroke recurrence rates did not differ 
between the treatment groups. 
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In a second trial, 10 patients with a National Institutes of Health Stroke Scale 
(NIHSS) score between 9 and 20 and within 7 days of stroke onset were 
randomised to 5 days of G-CSF (15 µg/kg per day, n=7) or control (routine 
care, n=3) (107). Over a 12-month follow-up, patients who received G-CSF 
had a significantly greater improvement in neurological function and disability 
than control patients. There was no aggravation of stroke symptoms and no 
thrombotic complications. Unfortunately, the results are confounded since 
many patients receiving G-CSF had a lacunar infarction, a type of stroke that 
often improves spontaneously. In the third trial, 15 patients were randomized 
within 1 week of stroke onset to receive G-CSF and 30 to placebo (108). A 
non-significant reduction in NIHSS was noted at day 10, which became 
significant at day 20. 
 
In a Cochrane systematic review of the three trials of G-CSF (as well as other 
colony stimulating factors) for stroke, G-CSF did not significantly alter 
functional outcome although there was a trend to reduced impairment (109). 
Furthermore, G-CSF was well tolerated and appeared to be safe, and 
significantly increased white cell count (109). The long term safety of G-CSF 
has been monitored in 101 normal donors who had G-CSF for the purpose of 
mobilising PBSCs prior to allogenic transplantation; there were no obvious 
adverse effects over a 3-6 year follow-up period and, in particular, the rates of 
cancer and vascular disease were not increased (110). Nevertheless, G-CSF 
may cause a hypercoagulable state (111), a potential mechanism for 
increasing recurrent stroke rates. In healthy donors receiving G-CSF, in vitro 
bleeding time is decreased with increased levels of Factor VIII and fibrinogen, 
and reduced protein C and S activity (111). 
 
Further trials of G-CSF are underway including a dose-escalation (30-
180g/kg) study in acute ischaemic stroke (n=44), a trial in sub-acute stroke 
(n=60), and a trial in 40 patients with chronic stroke (3 months from ictus); a 
non-controlled study is also ongoing (109). Data from these completed and 
ongoing trials will inform whether larger phase III trials of G-CSF are 
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warranted. Although other colony stimulating factors such as stem cell factor 
(SCF), granulocyte-macrophage-colony stimulating factor (GM-CSF) and 
macrophage-colony stimulating factor (M-CSF or CSF-1) also mobilise bone 
marrow-derived stem cells (and recombinant forms are available), trials in 
patients with stroke have not been reported (109). 
 
FUTURE DEVELOPMENT OF STEM CELLS FOR THE TREATMENT OF 
STROKE 
Although many studies assessing stem cells in pre-clinical stroke have been 
reported, and limited clinical trial data are now available, many questions 
remain unanswered. There is also a noticeable lack of published studies 
reporting a negative or neutral outcome. This publication bias can perpetuate 
the development of inappropriate clinical trials that will not answer the 
uncertainties that remain in this field (112). It is vital that future experimental 
studies are of high quality (for example, conforming to the STAIR criteria 
(113)) and have standardised protocols and outcome measures so they can be 
fairly compared. 
 
One possible advantage of treating stroke with stem cells is a potentially wide 
therapeutic window. The optimal time of administration post stroke will relate 
to the micro-environment of the damaged area, i.e. should stem cells be 
administered during the acute phase of stroke at a time when inflammatory 
responses are maximal or will delayed treatment be effective at a time when 
scar tissue has formed? The inflammatory response can last up to several 
weeks and it may be that stem cells could exacerbate or attenuate this 
process. Relatively few studies have analysed the effects of stem cells in 
intracerebral haemorrhage (ICH) but a reduction in inflammation was observed 
in one study assessing intravenous human neural stem cells in experimental 
ICH (114); the majority of the transplanted cells were detected in the marginal 
zones of the spleen with only very few seen in the brain sections. Adipose 
derived stem cells (ASCs) have also been transplanted into experimental ICH 
(115), and again, a reduction in the inflammatory response was seen but ASCs 
did not reveal any evidence of neuronal transdifferentiation.  
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The ideal route of stem cell delivery is also unclear. This has been addressed in 
one pre-clinical study comparing intra-striatal, intra-ventricular and 
intravenous administration of neural precursor cells with all routes resulting in 
cells targeting the lesion (116). In contrast to this, another study assessing 
intravenous administration of human umbilical cord cells in stroke rats did not 
detect any evidence of stem cells in the target lesion (117). If intracerebral 
administration is the most effective (though probably the most hazardous) 
then should cells be transplanted directly into the ischaemic lesion or distant to 
it (reducing the chance of damaging vital structures) and relying on 
spontaneous stem cell migration (76, 95, 118)? Existing human safety trials 
used intracerebral injections of stem cells directly into the peri-infarct area 
(98, 101), a decision appearing not to be based on any substantial pre-clinical 
work. The role of immunosupression in such exogenous transplants also 
remains elusive.  
 
There are multiple sources of exogenous stem cells available (at least 5 types 
of adult stem cells are in commercial development (119)) and the cell type 
that should be transplanted for a given stroke type and size is undetermined. 
Endogenous stem cell treatment is an attractive alternative, removing the 
need for immunosuppression. CD34+ stem cells can be mobilised into 
peripheral blood with G-CSF in ischaemic stroke patients in a dose dependent 
manner (106), but it may be the direct neuroprotective qualities of G-CSF that 
play a more important role. G-CSF already possesses a good safety record and 
pharmacological profile for use in humans and, though it is essential that 
thorough pre-clinical work precede human clinical trials (pre-clinical data on 
ideal doses and times of administration of G-CSF are still outstanding), the use 
of G-CSF and other colony stimulating factors such as erythropoietin have 
progressed to phase II and III stroke trials.  
 
CONCLUSION 
There is much hope and hype attached to the development of stem cell 
therapies. However, many questions remain to be answered and patients 
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should not, at present, undergo stem cell therapy out with a properly designed 
randomised controlled trial. 
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Cells Patients  
(active / 
control) 
Stroke type Administration Immunosuppression Comments 












Cyclosporine 1 week 
prior to surgery and 
continued for 8 weeks 
No effect on functional 















Cyclosporine 1 week 
prior to surgery and 
continued for 6 months 




Foetal porcine 5 (of planned 
12) / 0 
MCA infarct Stereotactic 
transplantation 
into region of the 
stroke 
None (cells pre-treated 
with anti-MHC antibody) 
Study stopped early 





5 / 25 MCA infarct Intravenous None Questionable study 
quality, e.g. 10 
patients lost to follow-
up 
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Table 2. Summary of human clinical trials in G-CSF and ischaemic stroke 
 











For 5 days 
Within 7 days 7 / 3 No thrombotic complications. 
Improved outcome in G-CSF 








For 1 or 5 days 
7-30 days post 
ictus 
24 / 12 No difference in SAEs 
although non-significant 






2 µg/kg/day s/c 
For 5 days 
Within 7 days 15 / 45 No difference in adverse 
events reported. Significant 
reduction in NIHSS 
SAE serious adverse event; s/c subcutaneous; NIHSS National Institutes of Health Stroke Scale 
 
